This ratio dropped to 45.45% (5/11) in t(8;21) AML patients with activating mutated KIT (7 with D816V, 2 with N822K, 1 with D816H, and 1 with D816Y) (Figure 2(F)). This evidence concerns the gene KIT and acute myeloid leukemia.